Regulatory
PRAC recommends lenalidomide label updates: an HLH warning and PML as a rare adverse reaction
Consider the new warning on haemophagocytic lymphohistiocytosis and the inclusion of PML as a rare adverse reaction to lenalidomide. The benefit–risk balance for approved indications remains unchanged.
#lenalidomide Державний експертний центр МОЗ України